Will Merck & Co. (NYSE: MRK) make money with Vaccines?

Merck (MRK) will manufacture the controversial Johnson & Johnson (JNJ) single-shot vaccine, U.S. President Joe Biden (D-Delaware) announced on 3 March 2021. Biden hopes Merck and J&J could manufacture enough vaccine for every adult in the United States by May 2021.
The contract could be lucrative because there were 255.2 million adults in the United States in 2019. However, the Johnson & Johnson (NYSE: JNJ) vaccine is controversial because it is weaker.

Read more